Stamford, CT (PRWEB) February 06, 2014 <\/p>\n
Alliance for Cancer Gene Therapy (ACGT) the nations only non-profit dedicated exclusively to cell and gene therapies for cancer is redoubling its efforts to treat and combat cancers in the New Year, and announces $1 million in recent grants. <\/p>\n
The funding spread across three grants will support basic and clinical science at premier institutions in and outside the United States, with ACGTs mission top-of-mind: uncovering effective, innovative cancer treatments that supersede radiation, chemotherapy and surgery. <\/p>\n
This January, ACGTs President and Co-Founder Barbara Netter has announced two Young Investigator Grants that provide promising researchers with $250,000 each for two- to three-year studies. <\/p>\n
Young Investigator Fan Yang, PhD Assistant Professor of Orthopedic Surgery and Bioengineering at Stanford University will use the funds to research new treatment options for pediatric brain cancer, the leading cause of death from childhood cancer. Dr. Yangs study will deploy adult-derived stem cells to target solid brain tumor cells, which are often highly invasive and difficult to treat. <\/p>\n
Arnob Banerjee, MD, PhD Assistant Professor of Hematology and Oncology at the University of Maryland will use ACGTs funding to further develop the long-term effectiveness of immune-mediated treatments, the most advanced form of gene therapy. <\/p>\n
It is imperative that the best and brightest young scientists like Fan Yang and Arnob Banerjee have the funds necessary to study and treat cancer, Netter said. This was my husband Edwards vision in 2001, when gene cell therapy was a fledgling science. We are proud to continue his pioneering foresight today. Partnerships with Dr. Yang, a former fellow at MIT, and Dr. Banerjee, a former fellow and instructor at the University of Pennsylvania, dovetail with ACGTs record of funding outstanding researchers and physicians with the capability to make unprecedented breakthroughs. <\/p>\n
The Young Investigator grants come on the heels of a $500,000 Investigators Award to John Bell, PhD, Senior Research Scientist and Professor of Medicine at the Ottawa Hospital Research Institute in Canada. Dr. Bell has worked extensively with oncolytic viruses man-made viruses that target only cancer cells, and spare patients the harrowing side-effects of chemotherapy, radiation or surgery and has discovered the enormous promise they offer in the war on cancer. <\/p>\n
The research and trials funded by ACGTs grant have the potential to treat metastatic and recurrent brain cancer, extend patients survival timeline, and vastly improve patients quality of life during treatment, Dr. Bell said. <\/p>\n
ACGT has served as a major funding engine in the fight against cancer since its formation in 2001, and has provided nearly $25 million in grants to date. ACGT was created by Barbara and Edward Netter after the loss of their daughter-in-law to breast cancer. Since Edwards passing in 2011, Barbara Netter has led the foundation as President and Co-Founder, continuing her husbands vision. <\/p>\n
<\/p>\n
Excerpt from: <\/p>\n
Alliance for Cancer Gene Therapy (ACGT) Targets Brain, Pediatric Cancers with $1 Million in New Grants<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Stamford, CT (PRWEB) February 06, 2014 Alliance for Cancer Gene Therapy (ACGT) the nations only non-profit dedicated exclusively to cell and gene therapies for cancer is redoubling its efforts to treat and combat cancers in the New Year, and announces $1 million in recent grants. The funding spread across three grants will support basic and clinical science at premier institutions in and outside the United States, with ACGTs mission top-of-mind: uncovering effective, innovative cancer treatments that supersede radiation, chemotherapy and surgery. This January, ACGTs President and Co-Founder Barbara Netter has announced two Young Investigator Grants that provide promising researchers with $250,000 each for two- to three-year studies. Continue reading